ARTICLE IN PRESSTHE JOURNAL0UROLOGYCheck forAUA Guideline Articlewww.auajournals.org/journal/juroupdatesEarly Detection of Prostate Cancer:AUA/SUO GuidelinePart ll:Considerations for a Prostate BiopsyJohn T.Wei,1*Daniel Barocas,2 Sigrid Carlsson,3 Fergus Coakley,4 Scott Eggener,5 Ruth Etzioni,sSamson W.Fine,3 Misop Han,7 Sennett K.Kim,3 Erin Kirkby,3 Badrinath R.Konety,3 Martin Miner,10Kelvin Moses,2 Merel G.Nissenberg,11 Peter A.Pinto,12 Simpa S.Salami,1 Lesley Souter,13lan M.Thompson,14 and Daniel W.Lin15University of Michigan,Ann Arbor,Michigan2Vanderbilt University,Nashville,TennesseeMemorial Sloan Kettering Cancer Center,New York,New YorkOregon Health Science University,Portland,OregonUniversity of Chicago,Chicago,Nlinois5Fred Hutchinson Cancer Center,Seattle,Washington7Johns Hopkins University,Baltimore,MarylandAmerican Urological Association,Linthicum,MarylandANina Health1Brown University,Providence,Rhode IslandNational Alliance of State Prostate Cancer Coalitions12National nstitues of Health,Bethesda,Maryland13Nomadic EBM Methodology14CHRISTUS Health15University of Washington,Seattle,WashingtonPurpose:The summary presented herein covers recommendations on the earlydetection of prostate cancer and provides a framework to facilitate clinicaldecision-making in the implementation of prostate cancer screening,biopsy,andfollow-up.This is Part II of a two-part series focusing on initial and repeat bi-opsies,and biopsy technique.Please refer to Part I for discussion of initialprostate cancer screening recommendations.Materials and Methods:The systematic review utilized to inform this guide-line was conducted by an independent methodological consultant.The sys-tematic review was based on searches in Ovid MEDLINE and Embase andCochrane Database of Systematic Reviews (January 1,2000-November 21,2022).Searches were supplemented by reviewing reference lists of relevantarticles.Results:The Early Detection of Prostate Cancer Panel developed evidence-and consensus-based guideline statements to provide guidance in prostatecancer screening,initial and repeat biopsies,and biopsy technique.Conclusions:The evaluation of prostate cancer risk should be focused onthe detection of clinically significant prostate cancer (grade group 2 or higher[GG2+]).The use of laboratory biomarkers,prostate MRI,and biopsy techniquesdescribed herein may improve detection and safety when a prostate biopsy isdeemed necessary following prostate cancer screening.Submitted April 10.2023:accepted April 12.2023:published 000.The complete unabridged version of the guideline is available at https://www.juology.com.This document is being printed as submitted.independent of standad editorial or peer review by the editors of The oual of ogy*Comespondence:Department of Uralogy.University of Michigan,1500 E Medical Center Drive,SPC 5330,3875TC.Ann Abor,M 48109-5330(包lephone:734-15300:email:jtwei@umich.ed山THE JOURNAL OF UROLOGYhttp5:∥doi.org/10.1097/JU.00000000000034922023 by AMERICAN UROLOGICA
